Cargando…
The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial
BACKGROUND: In 6-month anti-dementia drug trials, a 4-point change in the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) is held to be clinically important. We examined how this change compared with measures of clinical meaningfulness. METHODS: This is a secondary analysis o...
Autores principales: | Rockwood, Kenneth, Fay, Sherri, Gorman, Mary, Carver, Daniel, Graham, Janice E |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2034585/ https://www.ncbi.nlm.nih.gov/pubmed/17760991 http://dx.doi.org/10.1186/1471-2377-7-26 |
Ejemplares similares
-
Ada-WHIPS: explaining AdaBoost classification with applications in the health sciences
por: Hatwell, Julian, et al.
Publicado: (2020) -
State, trait, and accumulated features of the Alzheimer's Disease Assessment Scale Cognitive Subscale (ADAS‐Cog) in mild Alzheimer's disease
por: Cogo‐Moreira, Hugo, et al.
Publicado: (2023) -
Recent Advances in Fluorescent Labeling Techniques for Fluorescence Microscopy
por: Suzuki, Takeshi, et al.
Publicado: (2007) -
A new mini-open technique of arthroscopically assisted Latarjet
por: Taverna, Ettore, et al.
Publicado: (2020) -
New scoring methodology improves the sensitivity of the Alzheimer’s Disease Assessment Scale-Cognitive subscale (ADAS-Cog) in clinical trials
por: Verma, Nishant, et al.
Publicado: (2015)